-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insider Buying: Evolus, Inc. (NASDAQ:EOLS) Director Buys $11,760.98 in Stock
Insider Buying: Evolus, Inc. (NASDAQ:EOLS) Director Buys $11,760.98 in Stock
Evolus, Inc. (NASDAQ:EOLS – Get Rating) Director Robert Hayman bought 1,091 shares of the firm's stock in a transaction on Monday, September 12th. The shares were acquired at an average price of $10.78 per share, for a total transaction of $11,760.98. Following the transaction, the director now owns 10,000 shares in the company, valued at $107,800. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Robert Hayman also recently made the following trade(s):
Get Evolus alerts:- On Friday, September 9th, Robert Hayman bought 8,909 shares of Evolus stock. The shares were acquired at an average price of $10.35 per share, for a total transaction of $92,208.15.
- On Wednesday, September 7th, Robert Hayman purchased 4,967 shares of Evolus stock. The shares were purchased at an average price of $10.05 per share, for a total transaction of $49,918.35.
Evolus Price Performance
Shares of NASDAQ:EOLS opened at $10.16 on Friday. The company has a market cap of $569.93 million, a price-to-earnings ratio of -7.21 and a beta of 2.01. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.60 and a quick ratio of 2.36. The firm has a 50 day simple moving average of $10.86 and a 200 day simple moving average of $11.30. Evolus, Inc. has a one year low of $5.06 and a one year high of $14.34.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC assumed coverage on shares of Evolus in a research report on Thursday, June 23rd. They set a "buy" rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.33.Hedge Funds Weigh In On Evolus
Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Deerfield Management Company L.P. Series C lifted its stake in Evolus by 195.5% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,632,751 shares of the company's stock valued at $42,140,000 after purchasing an additional 2,403,517 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in Evolus by 521.0% in the 4th quarter. Stonepine Capital Management LLC now owns 1,863,096 shares of the company's stock valued at $12,129,000 after purchasing an additional 1,563,096 shares during the last quarter. AIGH Capital Management LLC bought a new position in Evolus in the 1st quarter valued at approximately $10,249,000. First Manhattan Co. lifted its stake in Evolus by 22.5% in the 1st quarter. First Manhattan Co. now owns 4,084,938 shares of the company's stock valued at $45,833,000 after purchasing an additional 750,022 shares during the last quarter. Finally, Schroder Investment Management Group lifted its stake in Evolus by 37.8% in the 4th quarter. Schroder Investment Management Group now owns 2,317,281 shares of the company's stock valued at $15,085,000 after purchasing an additional 636,109 shares during the last quarter. Institutional investors own 50.60% of the company's stock.
About Evolus
(Get Rating)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
- Get a free copy of the StockNews.com research report on Evolus (EOLS)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
Evolus, Inc. (NASDAQ:EOLS – Get Rating) Director Robert Hayman bought 1,091 shares of the firm's stock in a transaction on Monday, September 12th. The shares were acquired at an average price of $10.78 per share, for a total transaction of $11,760.98. Following the transaction, the director now owns 10,000 shares in the company, valued at $107,800. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
納斯達克:EOLS-GET評級)董事羅伯特·海曼在9月12日星期一的一筆交易中購買了該公司1,091股股票。這些股票是以每股10.78美元的平均價格收購的,總交易額為11,760.98美元。交易完成後,董事現在擁有該公司1萬股股份,價值10.78萬美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個超級鏈接獲得。
Robert Hayman also recently made the following trade(s):
羅伯特·海曼最近還進行了以下交易:
- On Friday, September 9th, Robert Hayman bought 8,909 shares of Evolus stock. The shares were acquired at an average price of $10.35 per share, for a total transaction of $92,208.15.
- On Wednesday, September 7th, Robert Hayman purchased 4,967 shares of Evolus stock. The shares were purchased at an average price of $10.05 per share, for a total transaction of $49,918.35.
- 9月9日,星期五,羅伯特·海曼購買了8,909股Evolus股票。這些股票是以每股10.35美元的平均價格收購的,總交易額為92,208.15美元。
- 9月7日,星期三,羅伯特·海曼購買了4967股Evolus股票。這些股票是以每股10.05美元的平均價格購買的,總交易額為49,918.35美元。
Evolus Price Performance
Evolus性價比
Shares of NASDAQ:EOLS opened at $10.16 on Friday. The company has a market cap of $569.93 million, a price-to-earnings ratio of -7.21 and a beta of 2.01. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.60 and a quick ratio of 2.36. The firm has a 50 day simple moving average of $10.86 and a 200 day simple moving average of $11.30. Evolus, Inc. has a one year low of $5.06 and a one year high of $14.34.
上週五,納斯達克股價開盤報10.16美元。該公司市值為5.6993億美元,市盈率為-7.21倍,貝塔係數為2.01。該公司的債務權益比為1.53,流動比率為2.60,速動比率為2.36。該公司的50日簡單移動均線切入位為10.86美元,200日簡單移動均線切入位為11.30美元。Evolus,Inc.的一年低點為5.06美元,一年高位為14.34美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Hedge Funds Weigh In On Evolus
對衝基金看好Evolus
Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Deerfield Management Company L.P. Series C lifted its stake in Evolus by 195.5% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,632,751 shares of the company's stock valued at $42,140,000 after purchasing an additional 2,403,517 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in Evolus by 521.0% in the 4th quarter. Stonepine Capital Management LLC now owns 1,863,096 shares of the company's stock valued at $12,129,000 after purchasing an additional 1,563,096 shares during the last quarter. AIGH Capital Management LLC bought a new position in Evolus in the 1st quarter valued at approximately $10,249,000. First Manhattan Co. lifted its stake in Evolus by 22.5% in the 1st quarter. First Manhattan Co. now owns 4,084,938 shares of the company's stock valued at $45,833,000 after purchasing an additional 750,022 shares during the last quarter. Finally, Schroder Investment Management Group lifted its stake in Evolus by 37.8% in the 4th quarter. Schroder Investment Management Group now owns 2,317,281 shares of the company's stock valued at $15,085,000 after purchasing an additional 636,109 shares during the last quarter. Institutional investors own 50.60% of the company's stock.
幾家機構投資者和對衝基金最近增持或減持了EOL的股份。Deerfield Management Company L.P.Series C在第二季度增持了195.5%的Evolus股份。Deerfield Management Company L.P.C系列現在擁有3632,751股該公司股票,價值42,140,000美元,在上個季度又購買了2,403,517股。Stonepine Capital Management LLC在第四季度增持了Evolus 521.0%的股份。Stonepine Capital Management LLC在上個季度額外購買了1,563,096股後,現在擁有1,863,096股該公司股票,價值12,129,000美元。Aigh Capital Management LLC在第一季度購買了Evolus的一個新頭寸,價值約為10,249,000美元。第一曼哈頓公司在第一季度增持了Evolus 22.5%的股份。第一曼哈頓公司目前持有該公司4,084,938股股票,價值45,833,000美元,上個季度又購買了750,022股。最後,施羅德投資管理集團在第四季度增持了37.8%的Evolus股份。施羅德投資管理集團在上個季度額外購買了636,109股票後,現在擁有2,317,281股該公司股票,價值15,085,000美元。機構投資者持有該公司50.60%的股票。
About Evolus
關於Evolus
(Get Rating)
(獲取評級)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Evolus,Inc.是一家性能美容公司,為美國的醫生和他們的患者提供醫療美容產品。它提供Jeuveau,一種專有的900kodalton純化A型肉毒毒素配方,用於暫時改善成人中到重度眉間線條的外觀。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Evolus (EOLS)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 免費獲取StockNews.com關於Evolus的研究報告(EOL)
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
- 沒有人告訴這三隻股票這是下跌的一週
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上,Arbor Realty Trust的股息值得嗎?
- 投資者應關注RF Industries
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Evolus Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Evolus和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧